Anti-Viral Peptidomimetic Development Service

Viruses invade human cells to reproduce themselves and cause infection, which may eventually lead to death. Therefore, it is urgent to develop better antiviral drugs to combat existing and emerging viral infections. CD BioSciences provides comprehensive development services for peptidomimetics with antiviral activity, helping global customers make greater progress in antiviral drug research and development.

Overview of Anti-Viral Peptides

Although rapid progress has been made in human medical care, infections caused by certain viruses such as human immunodeficiency virus, hepatitis virus, herpes simplex virus and influenza virus have resulted in high incidence rate and high mortality, which still cannot be completely cured, highlighting the importance of developing new antiviral drugs. In recent years, a large number of antiviral peptides have been found in animals, plants and microorganisms, which can exert antiviral effects by inhibiting virus invasion, viral protein synthesis and improving host immune function, providing a new source for the development of antiviral drugs. The hydrophobicity, charge, amphiphilicity and molecular weight of polypeptide are the main factors that affect the drug formation of polypeptide, and suitable polypeptide drugs should also have the characteristics of low toxicity and high selectivity.

Fig. 1 The life cycle of viruses. (Tompa, et al., 2021)

Advantages of Peptidomimetics

Scientists have turned their attention to peptidomimetic-based antiviral therapy, which is currently approved for human immunodeficiency virus (HIV), influenza and hepatitis viruses (B and C). There are more than 60 kinds of antiviral peptidomimetic drugs on the market in Europe, America and some Asian countries. In addition, the number of peptidomimetic drugs entering clinical trials is also increasing year by year, so the development of peptidomimetic drugs will become one of the effective strategies for antiviral therapy. Peptidomimetics have stronger stability than traditional peptide drugs and can resist the metabolic degradation pathway of the body to reach the action site. The optimization of the structure enables the peptidomimetics to be better targeted and exhibit better therapeutic potential as virus resistance increases.

Fig. 2 Model of SARS-CoV/ SARS-CoV-2 binding inhibition by S1 domain-based inhibitor peptides (A) and ACE2-derived inhibitor peptides (B). (Heydari, et al., 2021)

Our Services

CD BioSciences provides comprehensive anti-viral peptidomimetic development services. Using our PepDom^TM platform, we can develop antiviral peptidomimetics with multiple mechanisms of action against different types of viruses.

Our anti-viral peptidomimetic development services include but are not limited to:

Advantages of Our Peptidomimetics

CD BioSciences focuses on developing peptidomimetics with antiviral activity. As long as you provide the goals you are interested in, our professional team will solve them immediately. Welcome to contact us for the best solution.

References

1. Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021). Trends and strategies to combat viral infections: a review on fda approved antiviral drugs. International Journal of Biological Macromolecules, 172, 524-541.
2. Heydari, H., Golmohammadi, R., Mirnejad, R., Tebyanian, H., & Moghaddam, M. M. (2021). Antiviral peptides against coronaviridae family: a review. Peptides, 139.

Related Services